As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of NextCure, Inc. The largest reported stake is ADAR1 Capital Management, LLC's, at 15.8%. 17 filings are on record since August 19, 2025 (Schedule 13G, August 14, 2026).
Sell to companies like NextCure, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: JP Sailing Capital Ltd · Sole voting: 0 · Shared voting: 455,001 · Sole dispositive: 0 · Shared dispositive: 455,001 · SCHEDULE 13G, 2026-10-20
- · Reporting person: ADAR1 Capital Management, LLC · Sole voting: 0 · Shared voting: 722,419 · Sole dispositive: 0 · Shared dispositive: 722,419 · SCHEDULE 13G, 2026-08-14
- · Reporting person: Ikarian Capital, LLC · Sole voting: 0 · Shared voting: 502,672 · Sole dispositive: 0 · Shared dispositive: 502,672 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Squadron Master Fund LP · Sole voting: 0 · Shared voting: 64,464 · Sole dispositive: 0 · Shared dispositive: 64,464 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Affinity Asset Advisors, LLC · Sole voting: 274,073 · Shared voting: 0 · Sole dispositive: 274,073 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-08-13
NextCure, Inc. has 17 Schedule 13D or 13G filings on record since 2025-08-19. 7 holders' latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-07-14 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 15.8% | 722,419 | SCHEDULE 13G, 2026-08-14 | 2026-07-31 |
| Ikarian Capital, LLC | 9.99% | 502,672 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| JP Sailing Capital Ltd | 9.9% | 455,001 | SCHEDULE 13G, 2026-10-20 | 2026-09-30 |
| Simcere Zaiming, Inc. | 9.4% | 338,636 | SCHEDULE 13G/A, 2026-05-06 | 2025-12-31 |
| Adage Capital Management, L.P. | 7.67% | 277,202 | SCHEDULE 13G, 2026-08-12 | 2026-06-30 |
| Sofinnova Venture Partners IX, L.P. ("SVP IX") | 7.1% | 222,654 | SCHEDULE 13D/A, 2026-03-05 | 2025-12-19 |
| Affinity Asset Advisors, LLC | 6.4% | 274,073 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| SilverArc Capital Management, LLC | 4.9% | 176,057 | SCHEDULE 13G/A, 2026-05-13 | 2026-03-31 |
| Pfizer Inc. (IRS Identification No.: 13-5315170) | 3% | 157,646 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
| Squadron Master Fund LP | 1.6% | 64,464 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
Holding shares or following this stake? See who's behind NextCure, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on NextCure, Inc. and the records around it.
NextCure, Inc. elsewhere on the record
- Leadership changes Oct 2026
- Layoff notices Jul 2026
- Form D filing Dec 2025
- Who owns it
Companies that share a holder
- Sofinnova Venture Partners IX, L.P. ("SVP IX") also filed stake reports on 1 other company: ArriVent Biopharma, Inc. (Mar 2026)
- Pfizer Inc. (IRS Identification No.: 13-5315170) also filed stake reports on 4 other companies: TREX BIO, INC. (Oct 2026), ORIC Pharmaceuticals, Inc. (May 2026), Allogene Therapeutics, Inc. (Feb 2026)
- SilverArc Capital Management, LLC also filed stake reports on 8 other companies: Cellectar Biosciences Inc (Aug 2026), ELUTIA INC. (Aug 2026), TELA BIO, INC. (Aug 2026)
Watch NextCure, Inc.
Get an email when NextCure, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on NextCure, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on NextCure, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on NextCure, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 0 | 722,419 | 0 | 722,419 | SCHEDULE 13G, 2026-08-14 |
| Daniel Schneeberger | 0 | 722,419 | 0 | 722,419 | SCHEDULE 13G, 2026-08-14 |
| Ikarian Capital, LLC | 0 | 502,672 | 0 | 502,672 | SCHEDULE 13G/A, 2026-08-14 |
| Neil Shahrestani | 0 | 502,672 | 0 | 502,672 | SCHEDULE 13G/A, 2026-08-14 |
| JP Sailing Capital Ltd | 0 | 455,001 | 0 | 455,001 | SCHEDULE 13G, 2026-10-20 |
| Jianping Huang | 0 | 455,001 | 0 | 455,001 | SCHEDULE 13G, 2026-10-20 |
| Adage Capital Management, L.P. | 0 | 277,202 | 0 | 277,202 | SCHEDULE 13G, 2026-08-12 |
| Robert Atchinson | 0 | 277,202 | 0 | 277,202 | SCHEDULE 13G, 2026-08-12 |
| Phillip Gross | 0 | 277,202 | 0 | 277,202 | SCHEDULE 13G, 2026-08-12 |
| Affinity Asset Advisors, LLC | 274,073 | 0 | 274,073 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Michael Cho | 274,073 | 0 | 274,073 | 0 | SCHEDULE 13G/A, 2026-08-13 |
| Squadron Master Fund LP | 0 | 64,464 | 0 | 64,464 | SCHEDULE 13G/A, 2026-08-14 |
| Squadron Capital Management LLC | 0 | 64,464 | 0 | 64,464 | SCHEDULE 13G/A, 2026-08-14 |
| Matthew Sesterhenn | 0 | 64,464 | 0 | 64,464 | SCHEDULE 13G/A, 2026-08-14 |
| William Blank | 0 | 64,464 | 0 | 64,464 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies NextCure, Inc. by CUSIP 65343E207 and gives its principal executive office as 2850 QUARRY LAKE DRIVE, SUITE 280, BALTIMORE, MD 21209 (SCHEDULE 13G, 2026-10-20).
What the percentages are based on
9.9% for each Reporting Person (approximately 9.94% before rounding), based on 4,577,359 shares of Common Stock outstanding as of July 31, 2026, as reported in the Issuer?s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed on August 6, 2026.JP Sailing Capital Ltd, SCHEDULE 13G, 2026-10-20
Purpose of Transaction (Item 4)
Sofinnova Venture Partners IX, L.P. ("SVP IX")
The Reporting Persons hold their securities of the Issuer for investment purposes. Depending on the factors discussed herein, the Reporting Persons may, from time to time, acquire additional Common Stock and/or retain and/or sell all or a portion of the Common Stock held by the Reporting Persons in the open market or in privately negotiated transactions, and/or may distribute the Common Stock held by the Reporting Persons to their respective members or limited partners. Any actions the Reporting Persons might undertake will be dependent upon the Reporting Persons' review of numerous factors, including, among other things, the price levels of the Common Stock, general market and economic conditions, ongoing evaluation of the Issuer's business, financial condition, operations and prospects; the relative attractiveness of alternative business and investment opportunities, and other future developments. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.Item 4 of the SCHEDULE 13D/A filed 2026-03-05
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-19 | Simcere Zaiming, Inc. | 12.7% | SCHEDULE 13G |
| 2025-10-24 | Squadron Capital Management LLC | 6.5% | SCHEDULE 13G |
| 2025-11-14 | Affinity Healthcare Fund, LP | 7.17% | SCHEDULE 13G/A |
| 2026-01-29 | Affinity Asset Advisors, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-02-12 | SilverArc Capital Management, LLC | 5.02% | SCHEDULE 13G |
| 2026-02-13 | Pfizer Inc. (IRS Identification No.: 13-5315170) | 3% | SCHEDULE 13G/A |
| 2026-02-17 | Ikarian Capital, LLC | 9.99% | SCHEDULE 13G |
| 2026-02-17 | Squadron Master Fund LP | 9.9% | SCHEDULE 13G/A |
| 2026-03-05 | Sofinnova Venture Partners IX, L.P. ("SVP IX") | 7.1% | SCHEDULE 13D/A |
| 2026-05-06 | Simcere Zaiming, Inc. | 9.4% | SCHEDULE 13G/A |
| 2026-05-13 | SilverArc Capital Management, LLC | 4.9% | SCHEDULE 13G/A |
| 2026-08-12 | Adage Capital Management, L.P. | 7.67% | SCHEDULE 13G |
| 2026-08-13 | Affinity Asset Advisors, LLC | 6.4% | SCHEDULE 13G/A |
| 2026-08-14 | ADAR1 Capital Management, LLC | 15.8% | SCHEDULE 13G |
| 2026-08-14 | Ikarian Capital, LLC | 9.99% | SCHEDULE 13G/A |
| 2026-08-14 | Squadron Master Fund LP | 1.6% | SCHEDULE 13G/A |
| 2026-10-20 | JP Sailing Capital Ltd | 9.9% | SCHEDULE 13G |
Questions about who owns NextCure, Inc.
Who owns NextCure, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of NextCure, Inc.: ADAR1 Capital Management, LLC (15.8%, Schedule 13G, filed 2026-08-14), Ikarian Capital, LLC (9.99%, Schedule 13G/A, filed 2026-08-14), JP Sailing Capital Ltd (9.9%, Schedule 13G, filed 2026-10-20), Simcere Zaiming, Inc. (9.4%, Schedule 13G/A, filed 2026-05-06) and Adage Capital Management, L.P. (7.67%, Schedule 13G, filed 2026-08-12); 2 more are listed above.
Who are the largest shareholders of NextCure, Inc.?
By the share each holder's latest filing reports, the largest holders of NextCure, Inc. on this page are ADAR1 Capital Management, LLC (15.8%), Ikarian Capital, LLC (9.99%) and JP Sailing Capital Ltd (9.9%).
When did ADAR1 Capital Management, LLC buy into NextCure, Inc.?
The filings give report dates, not purchase dates. The earliest filing from ADAR1 Capital Management, LLC on this page is the Schedule 13G, filed 2026-08-14, reporting 15.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for NextCure, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 30, 2026 | Leadership change: Udayan Guha departs, Chief Medical Officer | — | Leadership changes | Source |
| July 14, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| December 10, 2025 | Form D, private offering | $21.50M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for NextCure, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.